VMAT2i
Medical abbreviation · Drug Class
| Stands for | Vesicular monoamine transporter 2 inhibitor |
|---|---|
| Categories | Medical |
VMAT2i stands for Vesicular monoamine transporter 2 inhibitor, a drug class abbreviation.
Drugs that reduce dopamine release by blocking its packaging into nerve vesicles: tetrabenazine, deutetrabenazine and valbenazine. They treat tardive dyskinesia and the chorea of Huntington disease.
Example: Moderate tardive dyskinesia on AIMS: start VMAT2i valbenazine 40 mg daily.
Usage notes
Valbenazine (Ingrezza), approved in 2017, was the first drug approved specifically for tardive dyskinesia; deutetrabenazine (Austedo) was approved the same year. Tetrabenazine and deutetrabenazine carry boxed warnings about depression and suicidality in Huntington disease. CYP2D6 genotype affects dosing for some agents.
Related abbreviations
More drug class abbreviations
- 3GC – Third-generation cephalosporin
- 5-ARI – 5-alpha reductase inhibitor
- 5-HT3 RA – 5-HT3 receptor antagonist
- AAD – Antiarrhythmic drug
- ACEI – Angiotensin-converting enzyme inhibitor
- AChEI – Acetylcholinesterase inhibitor
- ACT – Artemisinin-based combination therapy
- ADC – Antibody-drug conjugate
- AED – Antiepileptic drug
- AG – Aminoglycoside
- AGI – Alpha-glucosidase inhibitor
- AI – Aromatase inhibitor
See all 113 drug class abbreviations →
This entry is for general education and is not medical advice. Abbreviation use varies between institutions; always confirm in context.